Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Positive-Controlled, Four-Way Crossover Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Positive-Controlled, Four-Way Crossover Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motixafortide (Primary) ; Moxifloxacin
  • Indications Acute myeloid leukaemia; Aplastic anaemia; Chronic myeloid leukaemia; Gastric cancer; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Respiratory tract infections; SARS-CoV-2 acute respiratory disease; Stem cell mobilisation
  • Focus Pharmacokinetics
  • Sponsors BioLineRx

    • Most Recent Events

    • 16 Feb 2024 According to a BioLineRx media release, data from this study will be presented at the 2024 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), taking place February 21-24, 2024, in San Antonio, Texas.
    • 01 Jan 2023 Status changed from active, no longer recruiting to completed.
    • 27 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top